Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Elina Asikanius"'
Autor:
Michael U. Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse‐Jarres, Víctor Jiménez‐Yuste, Midori Shima, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Flora Peyvandi
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022)
Abstract Background Bleeding in people with hemophilia A can be life threatening, and intra‐articular bleeds can result in joint damage. Most clinical studies focus on treated bleeds, while bleeds not treated with coagulation factor(s) (untreated b
Externí odkaz:
https://doaj.org/article/e0003f2e961e49a1b507a404d3f16f57
Autor:
Benjamin Hofner, Elina Asikanius, Wolfgang Jacquet, Theodor Framke, Katrien Oude Rengerink, Lukas Aguirre Dávila, Maria Grünewald, Florian Klinglmüller, Martin Posch, Finbarr P. Leacy, Thomas Lang, Armin Koch, Jörg Zinserling, Kit Roes
The COVID-19 pandemic triggered an unprecedented research effort to develop vaccines and therapeutics. Urgency dictated that development and regulatory assessment were accelerated, while maintaining all standards for quality, safety and efficacy. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b519718a1153da6355ceb82cf9b52ef
Autor:
Michael U. Callaghan, Elina Asikanius, Johnny Mahlangu, Maria Elisa Mancuso, Christophe Schmitt, Michaela Lehle, Sammy Chebon, Víctor Jiménez-Yuste, Peter J. Kuebler, Markus Niggli, Rebecca Kruse-Jarres, Nives Selak Bienz, Ido Paz-Priel, Claude Negrier, Midori Shima, Guy Young, Steven W. Pipe, Tiffany Chang, Johannes Oldenburg, Gallia G. Levy
Publikováno v:
Blood. 136:3-5
Introduction: Emicizumab-a subcutaneously administered, bispecific, humanized, monoclonal antibody-promotes effective hemostasis in people with hemophilia A (PwHA). The primary efficacy and safety of emicizumab were reported previously, but long-term
Autor:
Sille Esbjerg, Elina Asikanius, Peter J. Kuebler, Soraya Benchikh El Fegoun, Gallia G. Levy, Stephanie Seremetis
Publikováno v:
Journal of Thrombosis and Haemostasis. 17:1470-1477
Background Recombinant activated factor VII (rFVIIa; eptacog alfa activated, NovoSeven® , Novo Nordisk A/S) is a bypassing agent used in congenital hemophilia A patients with inhibitors. Emicizumab (Hemlibra® ; F Hoffmann-La Roche Ltd) is a recombi
Autor:
Markus Niggli, Simone Schlagmüller, Elvira Schmidt, Susan C. Edwards, Max Zortel, Roger J. Hampton, Ido Paz-Priel, Sammy Chebon, Anadi Mahajan, J.-P. Flacke, Cedric Revil, Adriana Reyes, Elina Asikanius
Publikováno v:
Current Medical Research and Opinion. 35:2079-2087
Objectives: To compare the efficacy of emicizumab prophylaxis with that of factor VIII (FVIII) prophylaxis in patients with hemophilia A without inhibitors using two approaches: network meta-analyses (NMA) and additional sub-group analyses from the H
Autor:
Michaela Lehle, Rebecca Kruse-Jarres, Claudia Garcia, Michael Recht, Johnny Mahlangu, Peter Trask, Michael U. Callaghan, Renchi Yang, Johannes Oldenburg, Sylvia von Mackensen, Midori Shima, Maria Elisa Mancuso, Elina Asikanius, Gallia G. Levy, Harrison Macharia
Publikováno v:
Haemophilia
Introduction Real-world data (RWD) on health-related outcomes in persons with haemophilia A (PwHA) provide insights into patient needs and can guide clinical study design. A global, prospective, non-interventional study (NIS; NCT02476942) collected d
Autor:
Jerzy Windyga, Jin Xu, Peter Trask, Sylvia von Mackensen, Willem Bujan, Craig M. Kessler, Elena Santagostino, Midori Shima, Johannes Oldenburg, Guy Young, Rebecca Kruse-Jarres, Flora Peyvandi, Elina Asikanius, Johnny Mahlangu, Michael U. Callaghan, Claude Negrier
Publikováno v:
Haemophilia. 25:33-44
Introduction Persons with haemophilia A (PwHA) with inhibitors to factor VIII often experience decreased health-related outcomes. In HAVEN 1 (NCT02622321), there was a statistically significant reduction in bleeding with emicizumab prophylaxis versus
Autor:
Ido Paz-Priel, Michaela Lehle, Elina Asikanius, Sylvia von Mackensen, Peter Trask, Olivier Catalani
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 26(6)
The Haem-A-QoL is frequently utilized in haemophilia clinical trials and captures relevant aspects of disease impact. Thresholds for some domains 'Physical Health' (PH), 'SportsLeisure' (SL) and 'Total Score' (TS) have previously been identified to b
Autor:
Elvira Schmidt, Susan C. Edwards, Max Zortel, Sammy Chebon, Adriana Reyes, Markus Niggli, Ido Paz-Priel, Roger J. Hampton, Elina Asikanius, Simone Schlagmüller, Anadi Mahajan, J.-P. Flacke, Cedric Revil
Publikováno v:
Current medical research and opinion. 36(7)
Dear Editor,We thank Jain and Lethagen for the opportunity to clarify some points of interest.As outlined in Mahlangu et al.1, emicizumab prophylaxis has demonstrated a statistically significant an...
Autor:
Harrison Macharia, Elena Santagostino, Gallia G. Levy, Michael Recht, Maggie Moore, Elina Asikanius, Johnny Mahlangu, Michaela Lehle, Midori Shima, Michael U. Callaghan, Claudia Garcia, Johannes Oldenburg, Renchi Yang, Rebecca Kruse-Jarres
Publikováno v:
Haemophilia. 24:921-929
Introduction Prospectively collected, real-world data on bleeds, haemophilic treatment and safety outcomes in persons with haemophilia A (PwHA) with factor VIII (FVIII) inhibitors are limited. A prospective, global, multi-centre, non-interventional s